ZenasZenas raises $200m to advance autoimmune antibody therapy
临床2期突破性疗法临床3期基因疗法临床1期
来源: Pharmaceutical Technology
Zenas, which has recently raised $200m, is evaluating obexelimab in multiple autoimmune disorders, including IgG4-related disease, systemic lupus erythematosus, and more. Credit: Dilok Klaisataporn / Shutterstock.
US-based Zenas BioPharma has raised $200m in a Series C round to support the clinical development of its lead candidate, obexelimab.
The investors included multiple US-based venture capital companies such as SR One, New Enterprise Associates (NEA), Norwest Venture Partners, Delos Capital, and others. The Series C funds will go towards supporting the “mid to late stage” clinical development programmes of obexelimab, a bispecific antibody that targets CD19 and FcγRIIb. Zenas acquired the rights to the antibody from Xencor in 2021.
In September 2023, Bristol Myers Squibb (BMS) acquired the developmental and marketing rights to obexelimab in several Asia Pacific regions, including Australia, Hong Kong, Japan, Singapore, South Korea and Taiwan. BMS made an equity investment in and paid $50m upfront to ZenasZenas, which is also eligible for additional milestone-based payments.
Zenas is evaluating obexelimab in a placebo-controlled Phase III INDIGO trial (NCT05662241) as a subcutaneous treatment for IgG4-related disease (IgG4-RD), a chronic fibroinflammatory disease. The study is expected to enrol approximately 200 participants with IgG4-RD.
An open-label Phase II/III SApHiAre trial (NCT05786573) is also evaluating obexelimab as a treatment for warm autoimmune haemolytic anaemia (wAIHA). Both the IgG4-RD and wAIHA trials are expected to conclude in late 2025 or early 2026.
Preview
来源: Pharmaceutical Technology
FDA grants RMAT designation to Taysha’s Rett syndrome gene therapy
Preview
来源: Pharmaceutical Technology
Zenas also plans to start Phase II trials investigating the bifunctional antibody as a treatment for multiple sclerosis and systemic lupus erythematosus (SLE), for which obexelimab has previously shown mixed results as a treatment. In 2018, it failed to meet the primary endpoint of maintenance of improvement in SLE in a Phase II trial (NCT02725515). Additionally, the Xencor-sponsored trial did meet the secondary endpoint, with treated patients taking a median of 76% longer to show losses in improvement.
The current Series C funds add to the $118m in a Series B round that Zenas raised in 2022. Other autoimmune candidates in the company’s portfolio include ZB002, an anti-TNFα therapy, and ZB004, a cytotoxic T lymphocyte-associated antigen-4 immunoglobulin (CTLA-4-Ig) fusion protein. The two therapies were also acquired from Xencor.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。